PT Diagnos Laboratorium Utama Tbk (DGNS.JK)
IDR 210.0
(0.0%)
IDR 210.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.15 Billion IDR | -185.8% |
| 2022 | 17.65 Billion IDR | -78.27% |
| 2021 | 81.27 Billion IDR | 21.26% |
| 2020 | 67.02 Billion IDR | 407.68% |
| 2019 | 13.2 Billion IDR | 6.15% |
| 2018 | 12.43 Billion IDR | 541.17% |
| 2017 | 1.93 Billion IDR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 668.06 Million IDR | 123.75% |
| 2024 Q2 | -120.11 Million IDR | -117.98% |
| 2023 Q2 | -4.64 Billion IDR | -26.13% |
| 2023 Q3 | -2.89 Billion IDR | 37.58% |
| 2023 Q1 | -3.68 Billion IDR | -353.03% |
| 2023 FY | -14.03 Billion IDR | -179.47% |
| 2023 Q4 | -2.81 Billion IDR | 2.93% |
| 2022 Q4 | 1.45 Billion IDR | -45.37% |
| 2022 Q3 | 2.66 Billion IDR | 12.81% |
| 2022 Q2 | 2.35 Billion IDR | -79.14% |
| 2022 FY | 17.65 Billion IDR | -78.27% |
| 2022 Q1 | 11.31 Billion IDR | 430.17% |
| 2021 Q1 | 27.8 Billion IDR | -9.46% |
| 2021 FY | 81.27 Billion IDR | 21.26% |
| 2021 Q4 | -3.42 Billion IDR | -113.26% |
| 2021 Q2 | 31.07 Billion IDR | 11.78% |
| 2021 Q3 | 25.82 Billion IDR | -16.88% |
| 2020 Q4 | 30.7 Billion IDR | 22.07% |
| 2020 Q1 | 2.05 Billion IDR | -45.93% |
| 2020 FY | 67.02 Billion IDR | 407.68% |
| 2020 Q2 | 9.07 Billion IDR | 340.88% |
| 2020 Q3 | 25.15 Billion IDR | 177.29% |
| 2019 Q3 | 3.8 Billion IDR | 45.14% |
| 2019 Q2 | 2.62 Billion IDR | -0.0% |
| 2019 FY | 13.2 Billion IDR | 6.15% |
| 2019 Q1 | 2.62 Billion IDR | 0.0% |
| 2019 Q4 | 3.8 Billion IDR | 0.0% |
| 2018 FY | 12.43 Billion IDR | 541.17% |
| 2017 FY | 1.93 Billion IDR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| PT Prodia Widyahusada Tbk | 308.5 Billion IDR | 104.911% |